Shopping Cart
- Remove All
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | $42 | In Stock | |
25 mg | $67 | In Stock | |
50 mg | $97 | In Stock | |
100 mg | $148 | In Stock | |
200 mg | $249 | In Stock | |
500 mg | $349 | In Stock | |
1 mL x 10 mM (in DMSO) | $54 | In Stock |
Description | Pazopanib (GW786034), a small molecule inhibitor, inhibits multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits VEGFR-1, -2 and -3, c-kit and PDGF-R, which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated. |
In vitro | Mice demonstrated good tolerance to Pazopanib treatment without any noticeable weight differences across all groups. When compared to those treated with low doses (vehicle or 10 mg/kg Pazopanib), mice in the high-dose groups (30 mg/kg or 100 mg/kg Pazopanib) exhibited a significant reduction in tumor burden. |
In vivo | In all synovial sarcoma cell lines, including SYO-1 and HS-SY-II, Pazopanib exhibited dose-dependent inhibitory effects on growth. At a concentration of 1μg/ml, Pazopanib suppressed the proliferation of SYO-1 and HS-SY-II cells, achieving complete inhibition at 5μg/ml. Pazopanib effectively inhibited VEGFR2 phosphorylation (IC50: 8 nM) in VEGF-induced HUVEC cells. The growth of synovial sarcoma cells was hindered by Pazopanib due to the induction of G1 phase arrest. Unlike cells treated with the control vector, Pazopanib treatment resulted in the suppression of phosphorylation of Akt, GSK-3β, JNKs, p70 S6 kinase, and mTOR in SYO-1 cells. When Pazopanib concentration was increased between 20 mg/ml and 22.5 mg/ml, a consequent reduction in RPE cell viability was observed. |
Kinase Assay | VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated compound in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs[1]. |
Cell Research | Pazopanib is prepared in DMSO and then diluted to final concentration in medium[1]. The effect of Pazopanib on cell proliferation is measured using 5-bromo-2-deoxyuridine (BrdU) incorporation method using commercially available kits. HUVEC is seeded in medium containing 5% fetal bovine serum (FBS) in type 1 collagen coated 96-well plates and incubated overnight at 37°C, 5% CO2. The medium is aspirated from the cells, and various concentrations of Pazopanib in serum-free medium are added to each well. After 30 min, either VEGF (10 ng/mL) or bFGF (0.3 ng/mL) is added to the wells. Cells are incubated for an additional 72 h and BrdU (10 μM) is added during the last 18 to 24 h of incubation. At the end of incubation, BrdU incorporation in cells is measured by ELISA. Data are fitted with a curve described by the equation, y=Vmax(1?(x/(K+x))), where K is equal to the IC50[1]. |
Alias | GW786034 |
Molecular Weight | 437.52 |
Formula | C21H23N7O2S |
Cas No. | 444731-52-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||
Solubility Information | Ethanol: < 1 mg/mL (insoluble or slightly soluble) H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 20 mg/mL (45.71 mM) | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.